InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (20 ops.)
Insider track record
OtherDisclosed buys
5
Disclosed sells
20
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Novo Holdings A/S. Officer active across 15 companies, notably Spruce Biosciences, INC.. Cumulatively, 32 filings have been recorded. Breakdown: 5 buys · 20 sells. Total volume traded: €119.2m. History available since 19 May 2021. The latest transaction was disclosed on 1 May 2026 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Novo Holdings A/S
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations32 total
3,327,734 sharesVoting Common StockSEC:0001388325-26-000021:0
555,555 shares@ US$18.00100.0% of flowVoting Common StockSEC:0001388325-26-000021:1
Canonical exit: 30 Jul 2026 (T+90)
2,733,681 sharesVoting Common StockSEC:0001388325-25-000018:0
51,522 shares@ US$1.32641.0% of flowCOMMON STOCKSEC:0000950170-24-087061:0
658,809 shares@ €1.129411.9% of flowCOMMON STOCKSEC:0000950170-24-059965:0
465,021 shares@ US$0.75471.6% of flowCOMMON STOCKSEC:0001209191-24-005075:0
842,020 shares@ US$0.76843.0% of flowCOMMON STOCKSEC:0001209191-24-005017:0
1,912,316 shares@ US$0.88847.8% of flowCOMMON STOCKSEC:0001209191-24-004900:0
100,000 shares@ US$10.25100.0% of flowCOMMON STOCKSEC:0001209191-24-003423:0
Canonical exit: 9 May 2024 (T+90)
658,809 shares@ €1.392114.6% of flowCOMMON STOCKSEC:0001209191-24-003303:0
2,469,135 shares@ €1.844772.5% of flowCommon StockSEC:0001209191-23-045444:0
Canonical exit: 7 Nov 2023 (T+90)
1,900 shares@ US$2.76160.1% of flowCommon StockSEC:0001209191-23-042977:0
11,000 shares@ US$2.73650.8% of flowCommon StockSEC:0001209191-23-042670:0
200,937 shares@ US$2.634115.2% of flowCommon StockSEC:0001209191-23-040691:0
1,250,000 shares@ US$46.10100.0% of flowCommon StockSEC:0001209191-23-040057:0
8,437 shares@ US$1.79050.4% of flowCommon StockSEC:0001209191-23-040129:0
4,834 shares@ US$1.99440.3% of flowCommon StockSEC:0001209191-23-039545:0
100,000 shares@ US$7.0974100.0% of flowCommon StockSEC:0001209191-23-039541:0
10,002 shares@ US$2.030.6% of flowCommon StockSEC:0001209191-23-038567:0
900 shares@ US$2.06450.1% of flowCommon StockSEC:0001209191-23-037208:0
2,208,000 shares@ US$3.1733.0% of flowCOMMON STOCKSEC:0001209191-23-011156:0
Canonical exit: 17 May 2023 (T+90)
484,496 shares@ US$10.32100.0% of flowCOMMON STOCKSEC:0001209191-22-050258:0
Canonical exit: 13 Dec 2022 (T+90)
900,000 shares@ US$3.0082.5% of flowCOMMON STOCKSEC:0001209191-22-043049:0
800,000 shares@ US$2.00100.0% of flowCOMMON STOCKSEC:0001209191-22-042241:0
1,820 shares@ US$2.8997100.0% of flowCommon StockSEC:0001209191-22-013316:0
25 of 32 declarations
About Novo Holdings A/S
Novo Holdings A/S is a declarant with 32 filings in total. In the sampled recent filings, from 2021-05-21 to 2026-05-05, the reported amounts are EUR 21,031,368 for buys and EUR 98,126,437 for sells, and the modal transaction nature is Sale. The companies cited include Cyteir Therapeutics, Inc., IO Biotech, Inc., Spruce Biosciences, INC., Avalyn Pharma Inc., MapLight Therapeutics, Inc., and Metagenomi, Inc., with a 10% Owner role at Avalyn Pharma Inc.
